Key result
The timing of invasive management in NSTE-ACS involves pending clinical issues that vary according to individual patient risk profiles.
Why the study?
Does early invasive management improve outcomes in NSTE-ACS patients?
Does early invasive management improve outcomes in NSTE-ACS patients?
Answers are grounded in this paper and cite their sources.
Discusses the timing of invasive management and pending issues according to risk profiles in NSTE-ACS patients.
Timing of management and pending issues according to the risk profiles of NSTE-ACS patients. NSTEMI, non-ST-segment elevation myocardial infarction; GRACE, Global Registry of Acute Coronary Events; RCT, randomized controlled trial, hs-cTn, high-sensitivity cardiac troponin.
No takes yet. Share an insight, caveat, or question.
Guedeney et al. (2022) studied this question. The timing of invasive management in NSTE-ACS involves pending clinical issues that vary according to individual patient risk profiles.
Synapse has enriched 10 related papers. Consider them for comparative context: